Harmony Biosciences (HRMY) director granted 17,710 stock options at $27.74 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi reported receiving a stock option grant for 17,710 shares of common stock. The option has an exercise price of $27.74 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market trade.

The option will vest in 36 equal monthly installments beginning on May 2, 2026, meaning the right to exercise the option will phase in gradually over three years.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ignelzi Troy A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	17,710	$0.00	--

Holdings After Transaction: Stock Option — 17,710 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 17,710 options Exercise price: $27.74 per share Expiration date: April 2, 2036 +2 more

5 metrics

Stock options granted 17,710 options Grant covering 17,710 underlying common shares

Exercise price $27.74 per share Conversion/exercise price of the stock option

Expiration date April 2, 2036 Option term end date

Total options after grant 17,710 options Total derivative holdings following transaction

Vesting schedule 36 monthly installments Vests monthly starting May 2, 2026

Key Terms

Stock Option, exercise price, vesting, expiration date, +1 more

5 terms

Stock Option financial

"The stock option shall vest in 36 equal monthly installments"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "27.7400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shall vest in 36 equal monthly installments beginning on May 2, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date": "2036-04-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title": "Common Stock""

Form 4 Insider Transactions: What Each Field Means →

04/06/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ignelzi Troy A.

(Last)

(First)

(Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

630 W. GERMANTOWN PIKE, SUITE 215

(Street)

PLYMOUTH MEETING

PENNSYLVANIA

19462

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$27.74	04/02/2026		A		17,710		⁽¹⁾	04/02/2036	Common Stock	17,710	$0	17,710	D

Explanation of Responses:

1. The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026.

	/s/ Christian Ulrich, Attorney-in-Fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Troy A. Ignelzi report in this Harmony Biosciences (HRMY) Form 4?

Troy A. Ignelzi reported receiving a stock option grant for 17,710 shares of Harmony Biosciences common stock. The option is a compensation award, has a $27.74 exercise price, and represents an acquisition of derivative securities rather than an open-market stock purchase or sale.

What are the key terms of the HRMY stock option granted to Troy A. Ignelzi?

The grant covers 17,710 stock options with an exercise price of $27.74 per share and an expiration date of April 2, 2036. These options relate to an equal number of common shares and were awarded at no cost as part of director compensation.

How do the Harmony Biosciences (HRMY) options granted to Ignelzi vest?

The stock option vests in 36 equal monthly installments beginning on May 2, 2026. This means one thirty‑sixth of the grant becomes exercisable each month over three years, gradually increasing the portion Ignelzi can convert to common shares.

Does the Harmony Biosciences Form 4 show any stock sales or purchases by Troy A. Ignelzi?

The Form 4 shows no open-market stock purchases or sales by Troy A. Ignelzi. It reports only a grant of 17,710 stock options as a compensation-related acquisition, with zero purchase price at grant and no disposition of existing Harmony Biosciences shares.

How many Harmony Biosciences (HRMY) options does Ignelzi hold after this transaction?

After the reported transaction, Ignelzi holds 17,710 stock options directly, corresponding to 17,710 underlying Harmony Biosciences common shares. This entire amount reflects the newly granted award, as indicated by the total shares following the transaction in the filing.